Plus, Schwab changes up target-date series.
The pharmacy benefit manager's shares rose 14% Thursday on the news that St. Louis-based Express Scripts agreed to buy it in a cash and stock deal. If the gains hold, Magellan, which, with 3.29% of Medco's shares, is the company's biggest mutual fund owner, is sure to benefit. (Magellan was up 1.6% Thursday versus a gain of 1.4% for the S&P 500.) Morningstar data showed Magellan manager Harry Lange had been adding to the stock in recent quarters, making it his top holding as of the end of May. Medco fits with Lange's penchant for fast-growing companies that benefit from larger trends, in this case an aging population that will need more prescription drugs and health-care reforms that will extend insurance coverage to more Americans.
Medco has long been a big holding in Fidelity Select Health Care
Magellan has struggled to mount a sustained comeback since Lange took over in October 2005 from Bob Stansky, who also lagged the S&P 500 Index during his tenure. Some of Magellan's recent misfires include Nokia
It will take more than a one-day pop by one stock or even a broader rally to right Magellan, though. The fund ranks in the bottom fourth of the category for most short- and long-term trailing periods.
American Funds Growth Fund of America
Schwab Shakes Up Its Target-Date Series Again
Dan Kern, the lead portfolio manager for Schwab's Target Funds, the firm's target-date retirement lineup, has left the company in a move that could result in another overhaul of the firm's series.
Schwab is in the process of selecting a new permanent manager and reassessing the series' glide paths, asset allocations, and underlying investments. The shop's new chief investment officer, Omar Aguilar, is also looking to build out the asset-allocation research team.